George Institute for Global Health, Sydney, Australia.
J Gerontol A Biol Sci Med Sci. 2012 Feb;67(2):152-7. doi: 10.1093/gerona/glr065. Epub 2011 May 5.
We are living in an era of unprecedented aging, with over a billion older people expected to be alive within a few decades. Despite this predictable demographic, drug trials have not kept pace with change and we now have significant evidence-practice gaps. These have arisen due to inappropriate age limits in randomized controlled trials and the near-universal exclusion of frail older people from studies. Suggested solutions include the abolition of age limits in new randomized controlled trials, and the routine measurement of frailty, with a new generation of randomized controlled trials to establish whether treatments remain effective and safe in old age and increasing frailty. We should all have a personal interest in ensuring that drugs used in our old age are truly effective.
我们正生活在一个前所未有的老龄化时代,预计在未来几十年内,全球将有超过 10 亿老年人。尽管人口老龄化是可以预见的,但药物试验并没有跟上变化的步伐,我们现在存在明显的证据与实践差距。这是由于随机对照试验中不合适的年龄限制以及几乎普遍将体弱老年人排除在研究之外造成的。建议的解决方案包括在新的随机对照试验中废除年龄限制,并常规测量虚弱程度,开展新一代随机对照试验以确定在老年和衰弱程度增加的情况下,治疗方法是否仍然有效和安全。我们都应该有个人利益来确保我们老年时使用的药物确实有效。